Annexon reports significant progress with its priority programs and third quarter 2023 financial results

Company prioritizes greatest near-term value-driving programs: anx005 for guillain-barrÉ syndrome (gbs), anx007 for geographic atrophy (ga) and first-in-kind complement small molecule, anx1502

ANNX Ratings Summary

ANNX Quant Ranking